ArticleVaccine2010
Prevalence of high-risk indications for influenza vaccine varies by age, race, and income.
Article in Vaccine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 51 citations in OpenAlex.
- Modeling the Potential Impacts of Outpatient Antiviral Treatment in Reducing Influenza-Associated Hospitalizations in the United States.The Journal of infectious diseases · 2025Article
- Characteristics of children with influenza admitted to a pediatric hospital in Greece during the 2022/2023 and 2023/2024 seasons.European journal of pediatrics · 2025Observational
- Influenza Vaccination, Household Composition, and Race-Based Differences in Influenza Incidence: An Agent-Based Modeling Study.American journal of public health · 2025Article
- A Clinical and Economic Comparison of Cell-Based Versus Recombinant Influenza Vaccines in Adults 18-64 Years in the United States.Vaccines · 2024Article
- Rates of Lower Respiratory Tract Illness in US Adults by Age and Comorbidity Profile.Infectious diseases and therapy · 2024Article
- Exposure, Susceptibility, and Recovery: A Framework for Examining the Intersection of the Social and Physical Environments and Infectious Disease Risk.American journal of epidemiology · 2023Article
- Examining Influenza Vaccination Patterns Among Young Adults with Asthma: Insights into Knowledge, Attitudes, and Practices.Patient preference and adherence · 2023Article
- Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population.Vaccines · 2022Article
- Correlates of influenza vaccination among underserved Latinx middle-aged and older adults: a cross-sectional survey.BMC public health · 2022Article
- Roadmap for Sex-Responsive Influenza and COVID-19 Vaccine Research in Older Adults.Frontiers in aging · 2022Review
- Acceptance Rate of Influenza Vaccination Among Patients with Type II Diabetes.Journal of family medicine and primary care · 2022Article
- Risk conditions in children hospitalized with influenza in Norway, 2017-2019.BMC infectious diseases · 2020Article
- Inflammatory risk factors for hypertriglyceridemia in patients with severe influenza.The Journal of international medical research · 2020Article
- Pneumococcal Vaccination in Adults Aged ≥65 Years: Cost-Effectiveness and Health Impact in U.S. Populations.American journal of preventive medicine · 2020Article
- Influenza Vaccination among Underserved African-American Older Adults.BioMed research international · 2020Article
- Racial Disparities in Adult Pneumococcal Vaccination Indications and Pneumococcal Hospitalizations in the U.S.Journal of the National Medical Association · 2019Article
- Article
- Cost-effectiveness of increasing vaccination in high-risk adults aged 18-64 Years: a model-based decision analysis.BMC infectious diseases · 2018Article
- Cost-effectiveness of PCV13 vaccination in Belgian adults aged 65-84 years at elevated risk of pneumococcal infection.PloS one · 2018Article
- Does cost-effectiveness of influenza vaccine choice vary across the U.S.? An agent-based modeling study.Vaccine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Estimates of the proportions of the population who are at high risk of influenza complications because of prior health status or who are likely to have decreased vaccination response because of immunocompromising conditions would enhance public health planning and model-based projections. We estimate these proportions and how they vary by population subgroups using national data systems for 2006-2008. The proportion of individuals at increased risk of influenza complications because of health conditions varied 10-fold by age (4.2% of children <2 years to 47% of individuals >64 years). Age-specific prevalence differed substantially by gender, by racial/ethnic groups (with African Americans highest in all age groups) and by income. Individuals living in families with less than 200% of federal poverty level (FPL) were significantly more likely to have at least one of these health conditions, compared to individuals with 400% FPL or more (3-fold greater among <2 and 30% greater among >64 years). Among children, there were significantly elevated proportions in all regions compared to the West. The estimated prevalence of immunocompromising conditions ranged from 0.02% in young children to 6.14% older adults. However, national data on race/ethnicity and income are not available for most immunocompromising conditions, nor is it possible to fully identify the degree of overlap between persons with high-risk health conditions and with immunocompromising conditions. Modifications to current national data collection systems would enhance the value of these data for public health programs and influenza modeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.